ViralkumarKBhanderiMD

Oncology • Tallahassee, FL

Breast Cancer, Gastrointestinal Cancer, Hematologic Oncology, Thoracic Cancer

Physician

Join to view full profile

Dr. Bhanderi is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Bhanderi's full profile

Already have an account?

Office
2351 Phillips Rd
Tallahassee, FL 32308
Phone+1 850-877-8166

Fax+1 850-877-0431

Summary

Viralkumar Bhanderi, MD is an Oncology specialist based in Tallahassee, FL with sub-specialties in Breast Cancer, Gastrointestinal Cancer, Hematologic Oncology and Thoracic Cancer. His experience expands across various types of cancers and he has been extensively involved in several clinical trials. He is a respected scholar with notable publications in reputable medical journals. Dr. Bhanderi's education includes a fellowship and residency from the University of Florida and a medical degree from LSU School of Medicine in Shreveport. Additionally, he received a CMS Meaningful Use Stage 1 Certification from OncoEMR, Altos Solutions, Inc. between 2012-2014.

Education & Training

University of FloridaFellowship, Hematology and Medical Oncology, 2006 - 2008
University of FloridaResidency, Internal Medicine, 2002 - 2006
LSU School of Medicine in ShreveportClass of 2002

Certifications & Licensure

FL State Medical License 2008 - 2026
GA State Medical License 2005 - 2015
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification OncoEMR, Altos Solutions, Inc., 2012-2014

Clinical Trials

APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors Start of enrollment: 2017 Sep 27
Recruiting
Phase 2
Study of Tazemetostat Versus Placebo When Given in Combination With Lenalidomide and Rituximab in Participants With Relapsed/Refractory Follicular Lymphoma Start of enrollment: 2020 Jun 11
Recruiting
Phase 3
Study to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung Cancer Start of enrollment: 2020 May 28
Active, not recruiting
Phase 2
A Study of Efficacy and Safety of Fruquintinib (HMPL-013) in Participants With Metastatic Colorectal Cancer Start of enrollment: 2020 Aug 12
Active, not recruiting
Phase 3
Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer Start of enrollment: 2020 Jul 07
Active, not recruiting
Phase 1, Phase 2
Join now to see all

Publications & Presentations

PubMed

Ixazomib plus daratumumab and dexamethasone: Final analysis of a phase 2 study among patients with relapsed/refractory multiple myeloma.
Sosana Delimpasi, Meletios A Dimopoulos, Jan Straub, Argiris Symeonidis, Luděk Pour
American Journal of Hematology. 2024-09-01
30 citations
Randomized Phase 2 Studies of Checkpoint Inhibitors Alone or in Combination With Pegilodecakin in Patients With Metastatic NSCLC (CYPRESS 1 and CYPRESS 2)
David R. Spigel, Robert M. Jotte, John Nemunaitis, Merrill Kingman Shum, Jeffrey A. Schneider
Journal of Thoracic Oncology. 2021-02-01
24 citations
Association of diurnal blood pressure pattern with risk of hospitalization or death in men with heart failure.
Jaekyu Shin, Sharoen E. Kline, Mariellen J. Moore, Yan Gong, Viralkumar Bhanderi
Journal of Cardiac Failure. 2007-10-01